Resolution at extraordinary general meeting of Probi

On the extraordinary general meeting of Probi AB (publ) held today 29 June 2016,
it was resolved to authorise the Board of Directors to resolve on the issue of
new shares with preferential right for the company’s shareholders during the
period up to the company’s annual general meeting 2017. The total number of
shares that may be issued by virtue of the authorisation shall amount to the
number of shares corresponding to issue proceeds of approximately SEK
600,000,000, and shall be within the limits of the share capital. The purpose of
the authorisation is to enable financing of the company’s acquisition of U.S
probiotic company Nutraceutix’s operations. Other terms and conditions for the
new share issue shall be determined by the Board.

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops
effective and well-documented probiotics. Through its world-leading research,
Probi has created a strong product portfolio in the gastrointestinal health and
immune system niches. Probi’s products are available to consumers in more than
30 countries worldwide. Probi’s customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer Healthcare
segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on
Nasdaq Stockholm, Small Cap. Probi has about 4,000 shareholders. Read more at
www.probi.se.